{"id":26339,"date":"2020-09-03T13:00:00","date_gmt":"2020-09-03T13:00:00","guid":{"rendered":"https:\/\/ogkologos.com\/asco20-virtual-research-round-up-podcast-central-nervous-system-tumors-and-lymphoma\/"},"modified":"2024-11-03T15:16:19","modified_gmt":"2024-11-03T15:16:19","slug":"asco20-virtual-research-round-up-podcast-central-nervous-system-tumors-and-lymphoma","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/asco20-virtual-research-round-up-podcast-central-nervous-system-tumors-and-lymphoma\/","title":{"rendered":"ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and Lymphoma"},"content":{"rendered":"

In the annual Research Round Up podcast series, Cancer.Net Associate Editors answer the question, \u201cWhat was the most exciting or practice-changing research in your field presented at the ASCO20 Virtual Scientific Program?\u201d<\/em> In this final episode of 2020, 2 editors discuss a range of research presented in central nervous system (CNS) tumors and lymphoma.<\/p>\n

Listen below, and subscribe to Cancer.Net Podcasts on Apple Podcasts<\/a> or Google Play<\/a> to catch up on all the highlighted research from this year\u2019s meeting.<\/p>\n

<\/p>\n

Dr. Glenn Lesser, the 2020 Cancer.Net Associate Editor for Central Nervous System Tumors<\/a>, discusses new research in cancer that has started in the brain or spinal cord<\/a>, as well as cancer that has spread to the brain from another part of the body, called secondary or metastatic cancer.  <\/p>\n

First, he discusses a study on whether adding low-dose whole-brain radiation therapy<\/a> to standard chemotherapy<\/a> helps people with a specific type of non-Hodgkin lymphoma<\/a> called primary CNS lymphoma  live longer. [4:24] He also discusses a study that looked at whether adding a targeted therapy called tucatinib (Tukysa) to chemotherapy could treat HER2-positive breast cancer that has spread to the brain<\/a>. [7:47]<\/p>\n

<\/p>\n

Dr. Michael Williams, the 2020 Cancer.Net Associate Editor for Lymphoma<\/a>, discusses 3 studies across the field of lymphoma. First, he discusses a study that compared the immunotherapy drug pembrolizumab (Keytruda) with a standard treatment for Hodgkin lymphoma<\/a> that was resistant to the initial treatment, called refractory, or if it came back after treatment, called recurrent or relapsed. [13:58] Next, he discusses a study comparing 2 targeted therapy drugs, ibrutinib (Imbruvica) and zanubrutinib (Brukinsa), for people with a specific type of non-Hodgkin lymphoma known as Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma)<\/a>. [16:32] Finally, he discusses a study that looked at treating people with refractory or recurrent follicular lymphoma<\/a> with a chimeric antigen receptor (CAR) T-cell therapy called axicabtagene ciloleucel (Yescarta). [19:09]<\/p>\n

Disclosure information for this podcast\u2019s speakers can be found in their individual biographies, which are linked to in the paragraphs above.<\/p>\n

Was this podcast useful?<\/em><\/strong> Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript<\/a> is also available. For more information, visit the<\/em> Cancer.Net podcast page<\/em><\/a>.<\/span><\/em><\/p>\n

Cancer.Net podcasts are edited for length and content.<\/em><\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

In the annual Research Round Up podcast series, Cancer.Net Associate Editors answer the question, \u201cWhat was the most exciting or practice-changing research in your field presented at the ASCO20 Virtual Scientific Program?\u201d In this final episode of 2020, 2 editors discuss a range of research presented in central nervous system (CNS) tumors and lymphoma. Listen […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-26339","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=26339"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26339\/revisions"}],"predecessor-version":[{"id":45569,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26339\/revisions\/45569"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=26339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=26339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=26339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}